JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Silvestre, J.-S.
Right arrow Articles by Lévy, B. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Silvestre, J.-S.
Right arrow Articles by Lévy, B. I.

Vol. 303, Issue 3, 1038-1043, December 2002

Very-Low-Dose Combination of the Angiotensin-Converting Enzyme Inhibitor Perindopril and the Diuretic Indapamide Induces an Early and Sustained Increase in Neovascularization in Rat Ischemic Legs

Jean-Sébastien Silvestre, Nyam Kamsu-Kom, Michel Clergue, Micheline Duriez and Bernard I. Lévy

Institut National de la Santé et de la Recherche Médicale U541, Hôpital Lariboisière, Université Paris, Paris, France

After acute ischemia of tissues, neovascularization must be sufficient and fast enough to preserve tissue integrity and organ function, and may thus be considered as a therapeutic strategy. This study examined the possible role of the very-low-dose combination of perindopril (angiotensin-converting enzyme inhibitor) and indapamide (diuretic), used first-line in the treatment of essential hypertension, on ischemia-induced angiogenesis. Ischemia was produced by artery femoral occlusion in rats treated or not with the very-low-dose combination (perindopril 0.76 mg/kg/day + indapamide 0.24 mg/kg/day) or each component given alone at the same dosage for 3 and 28 days. At day 3, angiographic vessel density and laser Doppler perfusion data showed significant improvement in ischemic/nonischemic leg ratio by, respectively, 1.9-fold and 1.5-fold in rats treated with the very-low-dose combination when compared with controls (p < 0.05). This was associated with an increase in vascular endothelial growth factor (VEGF; 2.2-fold) and endothelial nitric-oxide synthase (1.6-fold) protein content in the ischemic hindlimb, assessed by Western blot. At day 28, the very-low-dose combination (3- and 1.6-fold) and perindopril alone (1.8- and 1.4-fold) and indapamide alone (2.0- and 1.4-fold) increased the angiograhic score and blood flow perfusion, respectively, in reference to controls (p < 0.05). Furthermore, addition of VEGF-neutralizing antibody (2.5 µg/kg twice a week) or NOS inhibitor (NG-nitro-L-arginine methyl ester, 10 mg/kg/day) prevented the pro-angiogenic effect induced by the perindopril/indapamide combination. The very-low-dose combination of perindopril and indapamide induces an early and sustained effect on the revascularization process observed in ischemic tissue and may provide a favorable therapeutic neovascularization after ischemia.

0022-3565/02/3033-1038$07.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Circ. Res.Home page
J. Vilar, L. Waeckel, P. Bonnin, C. Cochain, C. Loinard, M. Duriez, J.-S. Silvestre, and B. I. Levy
Chronic Hypoxia-Induced Angiogenesis Normalizes Blood Pressure in Spontaneously Hypertensive Rats
Circ. Res., September 26, 2008; 103(7): 761 - 769.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
B. I. Levy, E. L. Schiffrin, J.-J. Mourad, D. Agostini, E. Vicaut, M. E. Safar, and H. A.J. Struijker-Boudier
Impaired Tissue Perfusion: A Pathology Common to Hypertension, Obesity, and Diabetes Mellitus
Circulation, August 26, 2008; 118(9): 968 - 976.
[Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
D. You, C. Cochain, C. Loinard, J. Vilar, B. Mees, M. Duriez, B. I. Levy, and J.-S. Silvestre
Combination of the Angiotensin-Converting Enzyme Inhibitor Perindopril and the Diuretic Indapamide Activate Postnatal Vasculogenesis in Spontaneously Hypertensive Rats
J. Pharmacol. Exp. Ther., June 1, 2008; 325(3): 766 - 773.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
D. You, C. Cochain, C. Loinard, J. Vilar, B. Mees, M. Duriez, B. I. Levy, and J.-S. Silvestre
Hypertension Impairs Postnatal Vasculogenesis: Role of Antihypertensive Agents
Hypertension, June 1, 2008; 51(6): 1537 - 1544.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
M. E. Safar and P. Lacolley
Disturbance of macro- and microcirculation: relations with pulse pressure and cardiac organ damage
Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H1 - H7.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
S. Donnini, R. Solito, A. Giachetti, H. J. Granger, M. Ziche, and L. Morbidelli
Fibroblast Growth Factor-2 Mediates Angiotensin-Converting Enzyme Inhibitor-Induced Angiogenesis in Coronary Endothelium
J. Pharmacol. Exp. Ther., November 1, 2006; 319(2): 515 - 522.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
T. G. Ebrahimian, R. Tamarat, M. Clergue, M. Duriez, B. I. Levy, and J.-S. Silvestre
Dual Effect of Angiotensin-Converting Enzyme Inhibition on Angiogenesis in Type 1 Diabetic Mice
Arterioscler Thromb Vasc Biol, January 1, 2005; 25(1): 65 - 70.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
B. I. Levy
Can Angiotensin II Type 2 Receptors Have Deleterious Effects in Cardiovascular Disease?: Implications for Therapeutic Blockade of the Renin-Angiotensin System
Circulation, January 6, 2004; 109(1): 8 - 13.
[Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
A. H. Schmaier
The kallikrein-kinin and the renin-angiotensin systems have a multilayered interaction
Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2003; 285(1): R1 - R13.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics.